#Australia #Prostate Surgery #Perth #Orthocell #Remplir™

The Groundbreaking Impact of Remplir™ in Nerve-Sparing Prostate Cancer Surgery

In a significant advancement in the field of regenerative medicine, Orthocell Limited (ASX:OCC) has introduced its innovative nerve repair device, Remplir™, to urologists in Australia. This technology is being utilized in nerve-sparing robotic-assisted radical prostatectomies (RARP), marking a promising development for men facing prostate cancer surgery.

Addressing Post-Surgical Complications

Radical prostatectomy, while effective in treating prostate cancer, often leaves patients with a host of complications, particularly erectile dysfunction and urinary incontinence. Research indicates that as many as 80% of men experience erectile dysfunction and up to 35% suffer from urinary incontinence after undergoing the procedure. These side effects stem from potential damage to the peripheral nerves of the neurovascular bundle (NVB) surrounding the prostate.

The introduction of Remplir™ in surgical practices aims to mitigate these risks. With approximately 40 surgeries performed using this device thus far, early indications suggest an improvement in post-operative recovery for erectile function and urinary continence. This technique represents a significant leap forward, utilizing a device designed to protect and repair damaged nerves, thus facilitating better health outcomes for patients.

Clinical Data and Future Research

Orthocell is actively collecting clinical data on the early cases where Remplir™ has been employed during RARP, planning to release this data in the near future. The company is also committed to investing in further clinical research to solidify the evidence supporting Remplir's role in expanding nerve repair applications. As stated by Orthocell’s CEO, Paul Anderson, the use of this innovative device underscores its versatility across multiple surgical specialties, including orthopaedics, plastic and reconstructive surgery, and urology.

Expanding Market Potential

The potential market for Remplir™ is enormous, especially considering the global nerve repair market is valued at approximately $1.6 billion. Orthocell's outreach towards urologists not only reflects their commitment to advancing surgical practices but also points to a considerable opportunity for business growth. Effective partnerships with hospitals and distributors are being established to facilitate the adoption of Remplir™ in surgical settings across the globe.

Conclusion

Through its cutting-edge technology, Orthocell provides an invaluable tool for surgeons aiming to enhance patient recovery and minimize complications associated with prostate cancer surgery. The status and insights from the ongoing clinical trials will likely define the future landscape for nerve repair solutions. As Remplir™ gains traction within medical circles, it has the potential to redefine postoperative care for patients, moving towards a future where complications like erectile dysfunction and urinary incontinence are significantly reduced.